Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Mymd Pharmaceuticals Inc (MYMD)

Mymd Pharmaceuticals Inc (MYMD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,019
  • Shares Outstanding, K 38,058
  • Annual Sales, $ 0 K
  • Annual Income, $ -29,890 K
  • 60-Month Beta 0.79
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 4.38
Trade MYMD with:

Options Overview Details

View History
  • Implied Volatility 294.96% ( -84.52%)
  • Historical Volatility 99.73%
  • IV Percentile 98%
  • IV Rank 42.38%
  • IV High 676.18% on 06/06/22
  • IV Low 14.55% on 08/17/21
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 21
  • Put/Call OI Ratio 0.21
  • Today's Open Interest 1,648
  • Open Int (30-Day) 1,470

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.00 +2.50%
on 06/24/22
3.33 -38.35%
on 05/31/22
-0.35 (-14.58%)
since 05/24/22
3-Month
1.88 +9.04%
on 05/12/22
4.85 -57.73%
on 04/04/22
-1.62 (-44.14%)
since 03/24/22
52-Week
1.88 +9.04%
on 05/12/22
9.95 -79.40%
on 11/02/21
-3.86 (-65.31%)
since 06/24/21

Most Recent Stories

More News
MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. ® (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced further advancement...

MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals’ Lead Compound MYMD-1 Demonstrates Superior Anti-inflammatory Effects over Top-Selling Therapies in a Pivotal Preclinical Model of Rheumatoid Arthritis

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced positive new preclinical study...

MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced an acceleration in the pace...

MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that Dr. Adam Kaplin, Chief...

MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced that the first patient has...

MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan, today announced Phase 1 clinical trial data...

MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals Enters Oversold Territory (MYMD)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S....

MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company...

ORMP : 4.90 (-9.43%)
MYMD : 2.05 (-8.48%)
MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021

MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, today announced that it...

MYMD : 2.05 (-8.48%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

MyMD Pharmaceuticals Inc. is a clinical stage pharmaceutical company involved in developing therapeutic platforms. MyMD Pharmaceuticals Inc., formerly known as Akers Biosciences Inc., is based in Maryland.

See More

Key Turning Points

3rd Resistance Point 2.63
2nd Resistance Point 2.50
1st Resistance Point 2.27
Last Price 2.05
1st Support Level 1.91
2nd Support Level 1.78
3rd Support Level 1.55

See More

52-Week High 9.95
Fibonacci 61.8% 6.87
Fibonacci 50% 5.91
Fibonacci 38.2% 4.96
Last Price 2.05
52-Week Low 1.88

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar